全文获取类型
收费全文 | 97396篇 |
免费 | 7936篇 |
国内免费 | 179篇 |
专业分类
耳鼻咽喉 | 811篇 |
儿科学 | 3449篇 |
妇产科学 | 3045篇 |
基础医学 | 12085篇 |
口腔科学 | 1603篇 |
临床医学 | 15856篇 |
内科学 | 17892篇 |
皮肤病学 | 1454篇 |
神经病学 | 9096篇 |
特种医学 | 2112篇 |
外国民族医学 | 33篇 |
外科学 | 9499篇 |
综合类 | 1519篇 |
一般理论 | 143篇 |
预防医学 | 12778篇 |
眼科学 | 1286篇 |
药学 | 6242篇 |
2篇 | |
中国医学 | 130篇 |
肿瘤学 | 6476篇 |
出版年
2023年 | 516篇 |
2022年 | 366篇 |
2021年 | 1517篇 |
2020年 | 1237篇 |
2019年 | 2048篇 |
2018年 | 2299篇 |
2017年 | 1655篇 |
2016年 | 1857篇 |
2015年 | 2051篇 |
2014年 | 2761篇 |
2013年 | 4401篇 |
2012年 | 6267篇 |
2011年 | 6567篇 |
2010年 | 3589篇 |
2009年 | 3254篇 |
2008年 | 5842篇 |
2007年 | 6567篇 |
2006年 | 6315篇 |
2005年 | 6179篇 |
2004年 | 5862篇 |
2003年 | 5674篇 |
2002年 | 5315篇 |
2001年 | 1266篇 |
2000年 | 1099篇 |
1999年 | 1128篇 |
1998年 | 1094篇 |
1997年 | 787篇 |
1996年 | 745篇 |
1995年 | 816篇 |
1994年 | 771篇 |
1993年 | 735篇 |
1992年 | 886篇 |
1991年 | 800篇 |
1990年 | 766篇 |
1989年 | 728篇 |
1988年 | 676篇 |
1987年 | 672篇 |
1986年 | 602篇 |
1985年 | 711篇 |
1984年 | 655篇 |
1983年 | 584篇 |
1982年 | 651篇 |
1981年 | 580篇 |
1980年 | 530篇 |
1979年 | 509篇 |
1978年 | 451篇 |
1977年 | 373篇 |
1976年 | 394篇 |
1974年 | 393篇 |
1973年 | 393篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Mary Beth Nierengarten 《Cancer》2023,129(21):3354-3355
3.
Marike Gabrielson Mattias Hammarström Magnus Bäcklund Jenny Bergqvist Kristina Lång Ann H Rosendahl Signe Borgquist Roxanna Hellgren Kamila Czene Per Hall 《International journal of cancer. Journal international du cancer》2023,152(11):2362-2372
Tamoxifen prevents recurrence of breast cancer and is suggested for preventive risk-reducing therapy. Tamoxifen reduces mammographic density, a proxy for therapy response, but little is known about its effects in remodelling normal breast tissue. Our study, a substudy within the double-blinded dose-determination trial KARISMA, investigated tamoxifen-specific changes in breast tissue composition and histological markers in healthy women. We included 83 healthy women randomised to 6 months daily intake of 20, 10, 5, 2.5, 1 mg of tamoxifen or placebo. The groups were combined to “no dose” (0-1 mg), “low-dose” (2.5-5 mg) or “high-dose” (10-20 mg) of tamoxifen. Ultrasound-guided biopsies were collected before and after tamoxifen exposure. In each biopsy, epithelial, stromal and adipose tissues was quantified, and expression of epithelial and stromal Ki67, oestrogen receptor (ER) and progesterone receptor (PR) analysed. Mammographic density using STRATUS was measured at baseline and end-of-tamoxifen-exposure. We found that different doses of tamoxifen reduced mammographic density and glandular-epithelial area in premenopausal women and associated with reduced epithelium and increased adipose tissue. High-dose tamoxifen also decreased epithelial ER and PR expressions in premenopausal women. Premenopausal women with the greatest reduction in proliferation also had the greatest epithelial reduction. In postmenopausal women, high-dose tamoxifen decreased the epithelial area with no measurable density decrease. Tamoxifen at both low and high doses influences breast tissue composition and expression of histological markers in the normal breast. Our findings connect epithelial proliferation with tissue remodelling in premenopausal women and provide novel insights to understanding biological mechanisms of primary prevention with tamoxifen. 相似文献
4.
5.
6.
7.
Kayla Ann Andrews Joel S. Owen James McCarthy David Wesche Nathalie Gobeau Thaddeus H. Grasela Jrg J. Mhrle 《CTS Clinical and Translational Science》2021,14(2):712
Volunteer infection studies using the induced blood stage malaria (IBSM) model have been shown to facilitate antimalarial drug development. Such studies have traditionally been undertaken in single‐dose cohorts, as many as necessary to obtain the dose‐response relationship. To enhance ethical and logistic aspects of such studies, and to reduce the number of cohorts needed to establish the dose‐response relationship, we undertook a retrospective in silico analysis of previously accrued data to improve study design. A pharmacokinetic (PK)/pharmacodynamic (PD) model was developed from initial fictive‐cohort data for OZ439 (mixing the data of the three single‐dose cohorts as: n = 2 on 100 mg, 2 on 200 mg, and 4 on 500 mg). A three‐compartment model described OZ439 PKs. Net growth of parasites was modeled using a Gompertz function and drug‐induced parasite death using a Hill function. Parameter estimates for the PK and PD models were comparable for the multidose single‐cohort vs. the pooled analysis of all cohorts. Simulations based on the multidose single‐cohort design described the complete data from the original IBSM study. The novel design allows for the ascertainment of the PK/PD relationship early in the study, providing a basis for rational dose selection for subsequent cohorts and studies. Study Highlights
- WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
- WHAT QUESTION DID THIS STUDY ADDRESS?
- WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
- HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?
8.
9.
Lee Ann Baxter-Lowe 《Human immunology》2021,82(7):455-456
10.
Nicolas Mottet Roderick C.N. van den Bergh Erik Briers Thomas Van den Broeck Marcus G. Cumberbatch Maria De Santis Stefano Fanti Nicola Fossati Giorgio Gandaglia Silke Gillessen Nikos Grivas Jeremy Grummet Ann M. Henry Theodorus H. van der Kwast Thomas B. Lam Michael Lardas Matthew Liew Malcolm D. Mason Philip Cornford 《European urology》2021,79(2):243-262
ObjectiveTo present a summary of the 2020 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG) guidelines on screening, diagnosis, and local treatment of clinically localised prostate cancer (PCa).Evidence acquisitionThe panel performed a literature review of new data, covering the time frame between 2016 and 2020. The guidelines were updated and a strength rating for each recommendation was added based on a systematic review of the evidence.Evidence synthesisA risk-adapted strategy for identifying men who may develop PCa is advised, generally commencing at 50 yr of age and based on individualised life expectancy. Risk-adapted screening should be offered to men at increased risk from the age of 45 yr and to breast cancer susceptibility gene (BRCA) mutation carriers, who have been confirmed to be at risk of early and aggressive disease (mainly BRAC2), from around 40 yr of age. The use of multiparametric magnetic resonance imaging in order to avoid unnecessary biopsies is recommended. When a biopsy is performed, a combination of targeted and systematic biopsies must be offered. There is currently no place for the routine use of tissue-based biomarkers. Whilst prostate-specific membrane antigen positron emission tomography computed tomography is the most sensitive staging procedure, the lack of outcome benefit remains a major limitation. Active surveillance (AS) should always be discussed with low-risk patients, as well as with selected intermediate-risk patients with favourable International Society of Urological Pathology (ISUP) 2 lesions. Local therapies are addressed, as well as the AS journey and the management of persistent prostate-specific antigen after surgery. A strong recommendation to consider moderate hypofractionation in intermediate-risk patients is provided. Patients with cN1 PCa should be offered a local treatment combined with long-term hormonal treatment.ConclusionsThe evidence in the field of diagnosis, staging, and treatment of localised PCa is evolving rapidly. The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on PCa summarise the most recent findings and advice for their use in clinical practice. These PCa guidelines reflect the multidisciplinary nature of PCa management.Patient summaryUpdated prostate cancer guidelines are presented, addressing screening, diagnosis, and local treatment with curative intent. These guidelines rely on the available scientific evidence, and new insights will need to be considered and included on a regular basis. In some cases, the supporting evidence for new treatment options is not yet strong enough to provide a recommendation, which is why continuous updating is important. Patients must be fully informed of all relevant options and, together with their treating physicians, decide on the most optimal management for them. 相似文献